Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 2, 2009, Pages 81-84

  Gupta, Abha A ^a   Tyrrell, Pascal ^a   Valani, Rahim ^a   Benseler, Susanne ^a   Abdelhaleem, Mohamed ^a   Weitzman, Sheila ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Hemophagocytosis lymphohistiocytosis; Macrophage activation syndrome; Treatment

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; ETOPOSIDE; IMMUNOGLOBULIN; CYCLOSPORIN; STEROID;

ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; INFANT; MACROPHAGE ACTIVATION SYNDROME; MALE; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RHEUMATIC DISEASE; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; VIRUS INFECTION; BLOOD DISEASE; CAUSE OF DEATH; MORTALITY; RETROSPECTIVE STUDY;

ADOLESCENT; ADRENAL CORTEX HORMONES; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; ETOPOSIDE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MALE; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; STEROIDS; VIRUS DISEASES;

EID: 60849097890     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181923cb4     Document Type: Article

References (23)

1. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997;29:157-166.
2. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957-1959.
3. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461-473.
4. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14:827-834.
5. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocyto-sis. Pediatr Blood Cancer. 2007;48:124-131.
6. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367-2373.
7. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21: 245-253.
8. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598-604. 9. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106:561-566.
9. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965-971.
10. Ramanan A, Laxer R, Schneider R. Secondary haemophago-cytic syndromes associated with rheumatic diseases. In: Weitzman S, Egeler M, eds. Histocytic Disorders of Children and Adults. Cambridge: Cambridge University Press; 2005: 380-395.
11. Stephan JL, Kone-Paut I, Galambrun C, et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford). 2001;40:1285-1292.
12. Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemo-phagocytic lymphohistiocytosis. Blood. 1995;86:4706-4707.
13. Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005;7:R30-R37.
14. Wulffraat NM, Rijkers GT, Elst E, et al. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003;42:375-379.
15. Marcenaro S, Gallo F, Martini S, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistio-cytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood. 2006;108:2316-2323.
16. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19: 2665-2673.
17. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140:221-230.
18. Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10:197-203.
19. Imashuku S, Hibi S, Kuriyama K, et al. Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2000;36:339-346.
20. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325: 1682-1687.
21. Henter JIEG, Lubeck PO, Ost A. Myelodysplastic syndrome following epipodophyllotoxin therapy in familial hemophago-cytic lymphohistiocytosis. Pediatr Hematol Oncol. 1993;10: 163-168.
22. Kitazawa J, Ito E, Arai K, et al. Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistio-cytosis. Med Pediatr Oncol. 2001;37:153-154.
23. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81:59-61.